Does Ajovy (fremanezumab) affect menstrual cycles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Ajovy (Fremanezumab) Affect Menstrual Cycles?

Based on available evidence, there is no documented effect of fremanezumab on menstrual cycles. The drug's mechanism of action—selectively targeting calcitonin gene-related peptide (CGRP)—does not involve hormonal pathways that regulate menstruation, and clinical trials have not reported menstrual irregularities as adverse events.

Mechanism and Safety Profile

  • Fremanezumab is a fully humanized monoclonal antibody (IgG2Δa) that selectively targets CGRP, a vasodilatory neuropeptide involved in migraine pathophysiology, without affecting sex hormone pathways. 1

  • The most common adverse events reported across clinical trials include injection-site pain and upper respiratory tract infections, with no mention of menstrual cycle disturbances. 2

  • Unlike erenumab (another CGRP antagonist), fremanezumab has not been associated with development or worsening of hypertension in post-marketing studies, suggesting a favorable safety profile without systemic hormonal effects. 2

Clinical Trial Evidence

  • Large-scale studies including the UNITE trial (353 patients) and real-world effectiveness studies (165 patients) documented adverse events comprehensively but did not report menstrual irregularities. 3, 4

  • The drug has been studied in adult women (who comprised 88% of participants in major trials) without any reported menstrual cycle changes. 3

Hormonal Context

While sex hormones (estrogen and progesterone) do fluctuate during the menstrual cycle and can affect migraine patterns, fremanezumab does not interact with these hormonal pathways. 5

  • Estrogen levels naturally influence migraine frequency, particularly in menstrually-related migraine, but CGRP antagonism does not alter estrogen or progesterone production or metabolism. 6

  • Fremanezumab can be safely used throughout the menstrual cycle without requiring timing adjustments or dose modifications based on cycle phase. 2

Practical Considerations

  • Patients can initiate fremanezumab at any point in their menstrual cycle without concern for cycle disruption. 1

  • If menstrual irregularities occur after starting fremanezumab, alternative causes should be investigated rather than attributing them to the medication. 2

  • The medication does not require contraceptive considerations beyond standard reproductive planning, unlike medications such as valproate which is absolutely contraindicated in women of childbearing potential. 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.